Spike detoxifying formulation with fibrinolytic Nattokinase may provide you the support needed post COVID mRNA technology gene injection vaccine; as the science matures & develops, consult with your
by Paul Alexander
doctor on using this cheap, available, safe formulation from The Wellness Company (Foster Coulson); be sure to factor in allergies, if you are a bleeder (this is a blood thinner) or have intolerances
See link again:
I also draw your attention to a 2018 paper by Chen et al. on the role of nattokinase as a promising alternative in prevention and treatment of cardiovascular diseases.
Chen H, McGowan EM, Ren N, Lal S, Nassif N, Shad-Kaneez F, Qu X, Lin Y. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomark Insights. 2018 Jul 5;13:1177271918785130. doi: 10.1177/1177271918785130. PMID: 30013308; PMCID: PMC6043915.
‘Nattokinase (NK), the most active ingredient of natto, possesses a variety of favourable cardiovascular effects and the consumption of Natto has been linked to a reduction in CVD mortality…
Recent research has demonstrated that NK has potent fibrinolytic activity, antihypertensive, anti-atherosclerotic, and lipid-lowering, antiplatelet, and neuroprotective effects…
This review covers the major pharmacologic effects of NK with a focus on its clinical relevance to CVD. It outlines the advantages of NK and the outstanding issues pertaining to NK pharmacokinetics. Available evidence suggests that NK is a unique natural compound that possesses several key cardiovascular beneficial effects for patients with CVD and is therefore an ideal drug candidate for the prevention and treatment of CVD. Nattokinase is a promising alternative in the management of CVD.’
Our argument is that with advisement by your doctor, and the fact that people are suffering now due to the effects of the spike protein (virus and devastatingly the vaccine), then the Spike Recovery formulation may hold benefit. We ask that persons who are breast feeding, who are on blood thinning anti-thrombotic medications, and persons under 18 years of age do not take this and always consult your physicians.
‘In summary, compared with traditional antithrombotic and antihypertensive drugs, NK is characterised by high safety, low cost, simple production process, oral availability, and long in vivo half-life. As such, it is expected to become a new-generation drug for thrombotic disorders or CVDs. Although human trials and clinical studies demonstrate the clinical benefits of NK in the clinical settings, there remain a number of limitations. However, all the available data are encouraging and promising and further clinical trials are needed to fully examine the prospect of NK as an alternative medication to tPA, aspirin, warfarin, or newer anticoagulants in the management of CVD. In the near future, it is possible that patients with CVD may need only a single NK pill to replace multiple drugs administered for the prevention and management of CVD, including tPA, antihypertensives, statins, aspirin, and warfarin.’
I draw your attention to a prior substack by me:
See Dr. McCullough’s potent substack on nattokinase: